VEGFA / VEGF165, C-His, recombinant protein

Description of VEGFA / VEGF165, C-His, recombinant protein

General information on VEGFA / VEGF165, C-His, recombinant protein

Structure

VEGF165 is a member of the VEGF (vascular endothelial growth factor) family of proteins, which are composed of four structural domains: an N-terminal signal peptide, a pro-region, a VEGF homology domain and a C-terminal core domain. The VEGF165 protein is a 165-amino acid glycoprotein, which is secreted and binds to the extracellular matrix.

Activity

VEGF165 is a transcription factor that acts as a growth factor for endothelial cells, stimulating their proliferation and migration. It also regulates the formation of new blood vessels, or angiogenesis. Additionally, VEGF165 has been found to modulate the expression of other genes involved in angiogenesis, such as matrix metalloproteinases.

Application

VEGF165 has a wide range of applications, including cancer therapy. It has been used as an antibody-drug target, as well as a therapeutic agent for the treatment of various types of cancer. Additionally, VEGF165 has been used to treat cardiovascular diseases, such as coronary artery disease, and has been investigated as a potential therapeutic agent for diabetic retinopathy.

Bevacizumab Biosimilar - Anti-VEGF mAb binds to VEGFA / VEGF165, C-His, recombinant protein in indirect ELISA Assay

Immobilized VEGFA / VEGF165, C-His, recombinant protein (cat. No.PX-P5977) at 0.5µg/mL (100µL/well) can bind to Bevacizumab Biosimilar - Anti-VEGF mAb (cat. No.PX-TA1006) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450